In acute myeloid leukemia (AML), GLUT3 negatively regulates epidermal growth factor receptor (EGFR) activity and its downstream signaling pathways, contributing to tyrosine kinase inhibitors (TKIs) chemoresistance (Zhuang et al. 2018). The gene discussed is EGFR; the disease is acute myeloid leukemia.